Distinguished in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Wyndham H. Wilson

Oncology

Bethesda, MD

Clinical Trials:Currently Recruiting for 2 Trials

44 Years of Experience

Distinguished in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Bethesda, MD

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Wyndham Wilson is an Oncologist in Bethesda, Maryland. Dr. Wilson has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Burkitt Lymphoma.

His clinical research consists of co-authoring 167 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Specialties

Oncology

Licenses

Internal Medicine in WV

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Locations

Bethesda, MD 20892

Call: 301-435-2415

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Enrollment Status: Recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Biological

Study Drugs: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid

Study Phase: Phase 1/Phase 2

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol

Enrollment Status: Recruiting

Publish Date: September 30, 2025

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma

Enrollment Status: Completed

Publish Date: June 22, 2025

Intervention Type: Diagnostic test, Drug, Other, Procedure, Biological

Study Drugs: EPOCH, Rituximab

Study Phase: Phase 2

Treatment and Natural History Study of Lymphomatoid Granulomatosis

Enrollment Status: Completed

Publish Date: June 19, 2025

Intervention Type: Biological, Diagnostic test, Drug, Procedure

Study Drugs: IFN-Alpha, Rituximab, EPOCH

Study Phase: Phase 2

Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Drug, Biological

Study Drugs: Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells

Study Phase: Phase 1

Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas

Enrollment Status: Completed

Publish Date: September 04, 2024

Intervention Type: Drug, Biological

Study Drugs: Rituximab, filgrastim, EPOCH

Study Phase: Phase 2

A Phase 2 Multicenter, Investigator Initiated Study of Oral Ruxolitinib Phosphate for the Treatment of Relapsed or Refractory Diffuse Large B-Cell and Peripheral T-Cell Non-Hodgkin Lymphoma

Enrollment Status: Completed

Publish Date: October 05, 2023

Intervention Type: Drug, Other

Study Drug: Ruxolitinib Phosphate

Study Phase: Phase 2

Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma

Enrollment Status: Completed

Publish Date: January 31, 2023

Intervention Type: Biological, Drug

Study Drugs: EPOCH-R, GM-CSF, Idiotype Vaccine

Study Phase: Phase 2

View 6 Less Clinical Trials

172 Total Publications

The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

Journal: British journal of haematology

Published: March 28, 2025

View All 172 Publications

Similar Doctors

Elite in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Kieron M. Dunleavy

Oncology | Hematology

Elite in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Kieron M. Dunleavy

Oncology | Hematology

Regional Cancer Care Associates LLC

3800 Reservoir Rd Nw,

Washington, DC

(5.0 miles away)

202-444-3736

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Kieron Dunleavy is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Dunleavy is rated as an Elite provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Burkitt Lymphoma, and Bone Marrow Aspiration. Dr. Dunleavy is currently accepting new patients.

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Nancy M. Hardy

Oncology | Transplant Surgery

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Nancy M. Hardy

Oncology | Transplant Surgery

University Of Maryland Oncology Associates PA

22 S Green St,

Baltimore, MD

(33.2 miles away)

410-328-1230

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Nancy Hardy is an Oncologist and a Transplant Surgeon in Baltimore, Maryland. Dr. Hardy is rated as a Distinguished provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hardy is currently accepting new patients.

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Sowmini Medavaram

Hematology Oncology | Hematology | Oncology

Advanced in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Dr. Sowmini Medavaram

Hematology Oncology | Hematology | Oncology

West Virginia University Medical Corporation

2000 Foundation Way, Suite 2600,

Martinsburg, WV

(58.2 miles away)

304-267-1944

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Sowmini Medavaram is a Hematologist Oncology specialist and a Hematologist in Martinsburg, West Virginia. Dr. Medavaram is rated as an Advanced provider by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). Her top areas of expertise are Pleuropulmonary Blastoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Medavaram is currently accepting new patients.

VIEW MORE PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilson's expertise for a condition

ConditionClose